The University of Southampton
University of Southampton Institutional Repository

Safety profile of Rosuvastatin: results of a prescription-event monitoring study of 11,680 patients

Kasliwal, Rachna, Wilton, Lynda V., Cornelius, Victoria, Aurixh-Barrera, Beate and Shakir, Saad A.W. (2007) Safety profile of Rosuvastatin: results of a prescription-event monitoring study of 11,680 patients Drug Safety, 30, (2), pp. 157-170.

Record type: Article


Background and objective: Rosuvastatin is a lipid-lowering drug, the newest of a class of drugs called HMG-CoA reductase inhibitors, or `statins', launched in the UK in March 2003. Our objective was to monitor the post-marketing safety of this drug, prescribed in primary care in England, using prescription-event monitoring.

Methods: An observational cohort study in which patients were identified from dispensed prescriptions issued by primary care physicians/general practitioners (GPs) between August and December 2003. Demographic and clinical-event data were collected from questionnaires posted to GPs at least 6 months after the date of first prescription for each patient. Stratified analysis of specific events by starting dose of rosuvastatin was conducted. Follow-up and causality assessment of medically significant events was undertaken.

Results: The cohort comprised 11?680 patients (median age 64 years); 50.3% were males (5880 of 11 680). The median period of treatment was 9.8 months. Of these patients, 72.7% (n = 8494) were started on rosuvastatin 10 mg/day. A total of 17.5% (n = 2047) of the patients were reported to have stopped treatment with rosuvastatin. Myalgia was the most frequent reason for stopping rosuvastatin and the most frequently reported clinical event. A 2.5-fold increase in the rate of abnormal liver-function tests (LFTs) was observed for patients started on rosuvastatin 40 mg/day compared with those started on 10 mg/day (2.71; 95% CI 1.53, 4.53). No case of rhabdomyolysis was reported in this cohort.

Conclusion: Rosuvastatin was considered to be a reasonably well tolerated drug. In the majority of patients, rosuvastatin was prescribed in line with recommendations. Abnormality of LFTs was found to be more frequent with the 40 mg/day dosage of rosuvastatin. Results from this study should be taken into account together with those of other clinical and pharmacoepidemiological studies of rosuvastatin.
Keywords: Adverse drug reactions; Liver disorders; Muscle pain; Pharmacovigilance; Prescription event monitoring; Rhabdomyolysis; Rosuvastatin; Various toxicities

Document Type: Research article

Full text not available from this repository.

More information

Published date: 2007


Local EPrints ID: 162299
ISSN: 0114-5916
PURE UUID: 393215a7-0848-43eb-9d67-523d01f5f121

Catalogue record

Date deposited: 18 Aug 2010 10:35
Last modified: 18 Jul 2017 12:32

Export record


Author: Rachna Kasliwal
Author: Lynda V. Wilton
Author: Victoria Cornelius
Author: Beate Aurixh-Barrera
Author: Saad A.W. Shakir

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton:

ePrints Soton supports OAI 2.0 with a base URL of

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.